Model systems for studying the assembly, trafficking, and secretion of apoB lipoproteins using fluorescent fusion proteins
- PMID: 31888978
- PMCID: PMC7053841
- DOI: 10.1194/jlr.RA119000259
Model systems for studying the assembly, trafficking, and secretion of apoB lipoproteins using fluorescent fusion proteins
Abstract
apoB exists as apoB100 and apoB48, which are mainly found in hepatic VLDLs and intestinal chylomicrons, respectively. Elevated plasma levels of apoB-containing lipoproteins (Blps) contribute to coronary artery disease, diabetes, and other cardiometabolic conditions. Studying the mechanisms that drive the assembly, intracellular trafficking, secretion, and function of Blps remains challenging. Our understanding of the intracellular and intraorganism trafficking of Blps can be greatly enhanced, however, with the availability of fusion proteins that can help visualize Blp transport within cells and between tissues. We designed three plasmids expressing human apoB fluorescent fusion proteins: apoB48-GFP, apoB100-GFP, and apoB48-mCherry. In Cos-7 cells, transiently expressed fluorescent apoB proteins colocalized with calnexin and were only secreted if cells were cotransfected with microsomal triglyceride transfer protein. The secreted apoB-fusion proteins retained the fluorescent protein and were secreted as lipoproteins with flotation densities similar to plasma HDL and LDL. In a rat hepatoma McA-RH7777 cell line, the human apoB100 fusion protein was secreted as VLDL- and LDL-sized particles, and the apoB48 fusion proteins were secreted as LDL- and HDL-sized particles. To monitor lipoprotein trafficking in vivo, the apoB48-mCherry construct was transiently expressed in zebrafish larvae and was detected throughout the liver. These experiments show that the addition of fluorescent proteins to the C terminus of apoB does not disrupt their assembly, localization, secretion, or endocytosis. The availability of fluorescently labeled apoB proteins will facilitate the exploration of the assembly, degradation, and transport of Blps and help to identify novel compounds that interfere with these processes via high-throughput screening.
Keywords: apolipoprotein B; chylomicrons; low density lipoproteins; very low density lipoproteins.
Conflict of interest statement
The authors declare that they have no conflicts of interest with the contents of this article.
Figures






References
-
- Hussain M. M., Kancha R. K., Zhou Z., Luchoomun J., Zu H., and Bakillah A.. 1996. Chylomicron assembly and catabolism: role of apolipoproteins and receptors. Biochim. Biophys. Acta. 1300: 151–170. - PubMed
-
- Segrest J. P., Jones M. K., De Loof H., and Dashti N.. 2001. Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42: 1346–1367. - PubMed
-
- Bell-Quint J., Forte T., and Graham P.. 1981. Synthesis of two forms of apolipoprotein B by cultured rat hepatocytes. Biochem. Biophys. Res. Commun. 99: 700–706. - PubMed
-
- Chen S-H., Habib G., Yang C-Y., Gu Z-W., Lee B. R., Weng S-A., Silberman S. R., Cai S. J., Deslypere J. P., Rosseneu M., et al. . 1987. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science. 238: 363–366. - PubMed
-
- Powell L. M., Wallis S. C., Pease R. J., Edwards W. H., Knott T. J., and Scott J.. 1987. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell. 50: 831–840. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous